Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P11-2
- Development stage
- Unknown
- Lead developer
- Guangdong Pharmaceutical University
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
P11-2: sourced facts only. name: "Among them, P11-2 exhibited robust antitumor activity against MV4-11 cells (IC50 = 45 nM) by efficiently degrading MNK1 (DC50 = 11.92 nM, Dmax > 96%) mediated by the ubiquitin-proteasome system." [PMID:40334145]; target: "Among them, P11-2 exhibited robust antitumor activity against MV4-11 cells (IC50 = 45 nM) by efficiently degrading MNK1 (DC50 = 11.92 nM, Dmax > 96%) mediated by the ubiquitin-proteasome system." [PMID:40334145]; developer: "School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, P. R. China." [PMID:40334145]; modality: "Discovery of P11-2: A Potent First-in-Class MNK1-Targeting PROTAC Degrader for the Treatment of Cancer." [PMID:40334145]; stage: "In addition, P11-2 exhibited favorable PK profiles and robust antitumor effects in the xenograft model." [PMID:40334145]
02
Targets
MKNK1 (Mitogen‑activated protein kinase‑interacting serine/threonine-protein kinase 1)
Beyond the preview
Go deeper on P11-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P11-2.